Incidence et facteurs de risque de l’encéphalopathie à l’ifosfamide chez les patients suivis pour un sarcome

Tajino, 2010, Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity and risk factors, J Orthop Sci, 15, 104, 10.1007/s00776-009-1431-y Shin, 2011, Fatal Ifosfamide-induced metabolic encephalopathy in patients with recurrent epithelial ovarian cancer: report of two cases, Cancer Res Treat, 43, 260, 10.4143/crt.2011.43.4.260 Durand, 2007, Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy, Ann Oncol, 18, 808, 10.1093/annonc/mdm104 Danesh, 1989, Ifosfamide encephalopathy, J Toxicol Clin Toxicol, 27, 293, 10.3109/15563658908994426 Sweiss, 2008, Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature, Drug Saf, 31, 989, 10.2165/00002018-200831110-00003 David, 2005, Evaluating risk factors for the development of ifosfamide encephalopathy, Am J Clin Oncol, 28, 277, 10.1097/01.coc.0000158439.02724.5a Szabatura, 2015, An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center, J Oncol Pharm Pract, 21, 188, 10.1177/1078155214527143 Howell, 2008, Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant, J Oncol Pharm Pract, 14, 157, 10.1177/1078155208093930 Richards, 2011, Evaluation of methylene blue, thiamine, and/or albumin in the prevention of ifosfamide-related neurotoxicity, J Oncol Pharm Pract, 17, 372, 10.1177/1078155210385159 Kettle, 2010, Effectiveness of exogenous albumin administration for the prevention of ifosfamide-induced encephalopathy, Pharmacotherapy, 30, 812, 10.1592/phco.30.8.812 Lo, 2016, Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: a retrospective analysis, J Formos Med Assoc, 115, 744, 10.1016/j.jfma.2015.07.016 Filhon, 2016, Ifosfamide-induced encephalopathy due to a novel formulation of ifosfamide, Pediatr Blood Cancer, 63, 372, 10.1002/pbc.25724 Meanwell, 1986, Prediction of ifosfamide/mesna associated encephalopathy, Eur J Cancer, 22, 815, 10.1016/0277-5379(86)90368-8 Curtin, 1991, Ifosfamide-induced neurotoxicity, Gynecol Oncol, 42, 193, 10.1016/0090-8258(91)90344-5 Rieger, 2004, Incidence and severity of ifosfamide-induced encephalopathy, Anticancer Drugs, 15, 347, 10.1097/00001813-200404000-00006 Martin-Liberal, 2013, Clinical activity and tolerability of a 14-day infusional ifosfamide schedule in soft-tissue sarcoma, Sarcoma, 2013, 868973, 10.1155/2013/868973